SWX:ROPPharmaceuticals
Roche ASCO 2026 Breast Cancer Data May Reshape Outlook For Shares
Roche Group (SWX:ROP) and Genentech plan to present new clinical data across nine cancer medicines at the 2026 ASCO Annual Meeting.
The program includes breast cancer results that may be important for clinical practice, with a focus on giredestrant, a selective estrogen receptor degrader.
Data span both investigational and approved therapies, including antibody drug conjugates, bispecific antibodies, and treatments for several cancer types.
The breadth of readouts could influence treatment...